ArticleBJU international2012

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Stacy Loeb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.